Replies to post #705920 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

For God's sake, do you know what condition does Outlook's approved product treat, and what will Northwest Bio vaccine treat if approved?

And the price of each treatment, the market potential?

Yes, I have to assume you do not.

Wet AMD market revenue is significantly larger than GBM. Various numbers can be found, but all agree that it is several times larger than the GBM market,

[manibiotech]

“You guys are just talking heads. It's dangerous to invest with that kind of mindset!”

Wow

Here look at number of cases just in US and then look up world wide

https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html


https://www.gene.com/patients/disease-education/amd-fact-sheet


https://www.medicalnewstoday.com/articles/age-related-macular-degeneration-expected-to-affect-288-million-people-by-2040



And then educate yourself before preaching/scolding others

[dennisdave]

before you make an unbelievable fool of yourself Google the marketsize for wet AMD treatment. The market for GBM n or r is smaller than wet AMD treatment. The price of both treatments is irrelevant

I tell you at MC of between 100-200 millions Outlook

you would be wrong

The reason why I mentioned Outlook is that after UK AND EMA approval Outlook hardly showed an increase in value so far. Nowadays the stock market for nonrevenue biotechs responds almost solely to positive cashflow reports, either via licensing or sales or (rumored) buyout for nonrevenue biotech stocks. Unfortunately, Powers made it very clear at the last ASM that as such for NWBO, for the mid-term future, is out of the question.

You guys are just talking heads.

You can address me as singular Im not royalty.

but what MC would you give to Northwest Bio if DCVax is approved?

as I said most probably there will be no additional information provided by NWBO on how to commercialize DCVAXL. That is the reason I'm 1000% in agreement with Biggers post who, as am I, is FED up with this non-commerce passive keep dilution retail attitude of management.

I want to hear from $NWBO how they’ll get to revenues after MHRA Approval (binary) in a presentation posted to the company’s website. Don’t waste my time yapping the lawsuit, I only care about the Judge’s decision.

— Michael Bigger (@biggercapital) July 2, 2024

Therefore I think after UK approval the SP will hit $1.4-$1.5 and then fall back to the $1 area so multiply that with the OS if you want your MC

It's dangerous to invest with that kind of mindset!

Given the stupidy of your post sell on Monday